

# Shahneen Sandhu Mbbs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6539804/publications.pdf>

Version: 2024-02-01

131  
papers

16,795  
citations

38660

50  
h-index

16127

124  
g-index

132  
all docs

132  
docs citations

132  
times ranked

19029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. <i>European Urology Focus</i> , 2022, 8, 1157-1168.	1.6	26
2	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). <i>Clinical Cancer Research</i> , 2022, 28, 1518-1530.	3.2	41
3	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinomaâ€”The RAPPORT Trial. <i>European Urology</i> , 2022, 81, 364-372.	0.9	70
4	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 837-846.	0.8	29
5	Characterization of the treatment-naïve immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
6	Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. <i>Prostate</i> , 2022, 82, 993-1002.	1.2	2
7	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
8	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. <i>Investigational New Drugs</i> , 2022, 40, 1051-1065.	1.2	4
9	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of <sup>177</sup> Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5027-5027.	0.8	1
10	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5004-LBA5004.	0.8	29
11	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9605-TPS9605.	0.8	19
12	DETECTION phase II/III trial: Circulating tumor DNAâ€”guided therapy for stage IIB/C melanoma after surgical resection.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9603-TPS9603.	0.8	3
13	TheraP: <sup>177</sup> Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxelâ€”Overall survival after median follow-up of 3 years (ANZUP 1603).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5000-5000.	0.8	44
14	PRINCE: Phase I trial of <sup>177</sup> Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5017-5017.	0.8	15
15	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of <sup>177</sup> Lu-PSMA-617 Prior to Prostatectomy. <i>European Urology Focus</i> , 2021, 7, 234-237.	1.6	31
16	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. <i>Cell Reports</i> , 2021, 34, 108585.	2.9	33
17	[ <sup>177</sup> Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804.	6.3	552
18	Î³ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021, 9, 612-623.	1.6	22

#	ARTICLE	IF	CITATIONS
19	Reply to E. Hindi. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
20	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer, 2021, 147, 74-83.	1.3	42
21	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
22	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 2021, 13, 2334.	1.7	9
23	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discovery, 2021, 26, 1107-1124.	1.4	30
24	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12
25	ENZA trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 2021, 128, 642-651.	1.3	18
26	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	5.8	33
27	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. Clinical Genitourinary Cancer, 2021, 19, e200-e205.	0.9	16
28	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	1.9	9
29	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	5.1	120
30	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	0.9	28
31	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	6.3	240
32	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Investigational New Drugs, 2020, 38, 844-854.	1.2	15
33	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup> Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 857-865.	2.8	191
34	18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. PET Clinics, 2020, 15, 11-22.	1.5	22
35	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	3.4	287
36	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	0.6	27

#	ARTICLE	IF	CITATIONS
37	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	1.3	31
38	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	5.1	450
39	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. , 2020, 8, e000700.		8
40	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
41	i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. <i>BMJ Open</i> , 2020, 10, e036059.	0.8	8
42	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	1.1	20
43	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 312-319.	0.7	13
44	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
45	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
46	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	0.6	62
47	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
48	Efficacy and Safety of <sup>177</sup> Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	0.9	39
49	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
50	Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study. <i>Quality of Life Research</i> , 2020, 29, 2021-2027.	1.5	11
51	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [ <sup>177</sup> Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2322-2327.	3.3	101
52	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
53	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	13.9	1,327
54	Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. <i>EMBO Reports</i> , 2020, 21, e50162.	2.0	58

#	ARTICLE	IF	CITATIONS
55	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 4064-4071.	3.2	50
56	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	3.3	42
57	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	3.9	68
58	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	3.9	180
59	Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. <i>BMC Medical Genomics</i> , 2019, 12, 115.	0.7	10
60	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019, 2, 670-676.	2.6	134
61	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019, 36, 385-401.e8.	7.7	359
62	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. <i>Prostate</i> , 2019, 79, 1326-1337.	1.2	12
63	Microbiome transplantation and modulation of immune related adverse events. <i>EClinicalMedicine</i> , 2019, 8, 10-11.	3.2	7
64	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
65	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. <i>Journal of Cancer Survivorship</i> , 2019, 13, 503-511.	1.5	31
66	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
67	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. <i>Neoplasia</i> , 2019, 21, 389-400.	2.3	20
68	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. <i>Annals of Oncology</i> , 2019, 30, 804-814.	0.6	117
69	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115.	0.6	29
70	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	1.2	18
71	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. <i>IScience</i> , 2019, 22, 1-15.	1.9	11
72	Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. <i>European Urology</i> , 2019, 75, 927-928.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Dosimetry of <sup>177</sup> Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 517-523.	2.8	285
74	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
75	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
76	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018, 73, 687-693.	0.9	99
77	Prostate-specific membrane antigen theranostics. <i>Current Opinion in Urology</i> , 2018, 28, 197-204.	0.9	39
78	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 722-723.	0.8	2
79	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	1.3	53
80	[ <sup>177</sup> Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply. <i>Lancet Oncology</i> , The, 2018, 19, e373.	5.1	10
81	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	0.9	80
82	[ <sup>177</sup> Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 825-833.	5.1	823
83	Mortality due to immunotherapy related hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 976-978.	1.8	34
84	Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection. <i>European Urology</i> , 2017, 71, 883-885.	0.9	2
85	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. <i>European Urology</i> , 2017, 71, 748-749.	0.9	9
86	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	7.7	341
87	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the "Australian guidelines for the management of cutaneous melanoma". <i>Australasian Journal of Dermatology</i> , 2017, 58, 274-277.	0.4	12
88	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , 2017, 23, 6070-6077.	3.2	30
89	Relevance of DNA damage repair in the management of prostate cancer. <i>Current Problems in Cancer</i> , 2017, 41, 287-301.	1.0	16
90	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 368-376.	0.6	641

#	ARTICLE	IF	CITATIONS
91	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , 2017, 283, 168-177.	3.6	81
92	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	51
93	E6AP promotes prostate cancer by reducing p27 expression. <i>Oncotarget</i> , 2017, 8, 42939-42948.	0.8	25
94	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016, 61, 111-121.	1.3	51
95	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
96	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5539-5552.	3.2	59
97	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 637-646.	2.5	30
98	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2016, 114, 889-896.	2.9	46
99	Use of vemurafenib in a patient unable to swallow whole. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 733-737.	0.5	6
100	Integration of Immuno-Oncology and Palliative Care. <i>Journal of Clinical Oncology</i> , 2016, 34, 1561-1562.	0.8	10
101	The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1174-1177.	0.6	53
102	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.4	270
103	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 37-47.	1.9	60
104	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
105	Cell cycle control as a promising target in melanoma. <i>Current Opinion in Oncology</i> , 2015, 27, 141-150.	1.1	67
106	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	13.9	1,796
107	Reply: â€˜Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancerâ€™. <i>British Journal of Cancer</i> , 2014, 110, 267-268.	2.9	1
108	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 504-508.	0.6	70

#	ARTICLE	IF	CITATIONS
109	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	3.2	36
110	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2013, 14, 882-892.	5.1	497
111	A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1041-1050.	1.1	216
112	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	3.2	126
113	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). <i>Annals of Oncology</i> , 2013, 24, 1807-1812.	0.6	310
114	Secondary mutations in <i>BRCA2</i> associated with clinical resistance to a PARP inhibitor. <i>Journal of Pathology</i> , 2013, 229, 422-429.	2.1	287
115	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. <i>European Urology</i> , 2013, 64, 300-306.	0.9	85
116	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline <i>BRCA2</i> mutant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 1416-1418.	0.6	62
117	Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1020-1027.	1.0	29
118	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	2.9	18
119	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012, 23, 2943-2947.	0.6	224
120	Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. <i>British Journal of Cancer</i> , 2012, 106, 1728-1734.	2.9	31
121	Toward a Better Dialogue Between Neuro-Oncologists and Phase I Investigators. <i>Journal of Clinical Oncology</i> , 2012, 30, 562-563.	0.8	3
122	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology</i> , The, 2012, 13, 1114-1124.	5.1	125
123	PARP Inhibitors. <i>Drugs</i> , 2012, 72, 1579-1590.	4.9	36
124	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 302-306.	12.5	120
125	HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine. <i>Current Drug Targets</i> , 2011, 12, 2045-2058.	1.0	30
126	Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 31-49.	157.7	178



#	ARTICLE	IF	CITATIONS
127	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. <i>Cancer Cell</i> , 2011, 19, 573-574.	7.7	15
128	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5188-5196.	3.2	29
129	The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment. <i>Current Drug Targets</i> , 2011, 12, 2034-2044.	1.0	32
130	Envisioning the future of early anticancer drug development. <i>Nature Reviews Cancer</i> , 2010, 10, 514-523.	12.8	262
131	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. <i>European Journal of Cancer</i> , 2010, 46, 9-20.	1.3	108